Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial

Antoni Chan, Jon Wood, Lachrissa Burns, Thomas Kumke, Bengt Hoepken, Mindy Kim, Lars Bauer, Kirsten Mackay, Karl Gaffney · 2026

Read Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial by Antoni Chan, Jon Wood, Lachrissa Burns, Thomas Kumke, Bengt Hoepken, Mindy Kim, Lars Bauer, Kirsten Mackay, Karl Gaffney (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13425177.txt.

Description

Antoni Chan and co-authors report patient-reported outcomes from a trial of dose reduction in early axial spondyloarthritis. Their 2026 paper covers the randomized phase of the C-OPTIMISE study. Patients with this spinal inflammatory disease had reached sustained remission on certolizumab pegol, a biologic drug, after forty-eight weeks of open treatment.

Of seven hundred thirty-six patients, about forty-four percent held remission at that point. They were then assigned in equal shares to full dose, reduced dose, or placebo for another forty-eight weeks. Scores for disease activity, function, night pain, and quality of life were tracked. Gains held up on both drug doses through week ninety-six, the authors report.

Catalog record

CREATORAntoni Chan, Jon Wood, Lachrissa Burns, Thomas Kumke, Bengt Hoepken, Mindy Kim, Lars Bauer, Kirsten Mackay, Karl Gaffney
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13425177

Browse the full library · About the Tower of Babel